LBS Healthcare Conference 2024

Day 1- 3rd April 2024

Dr. David Pyott | Opening Remarks

Chairman for London Business School, Board Member of Philips, Alnylam Pharmaceuticals, BioMarin Pharmaceutical and Former Chairman and CEO at Allergan

Dr. David Pyott is an accomplished international pharmaceutical executive with more than 30 years of leadership and management experience with particular expertise in organizational scaling.

Most recently, he served as Chairman and Chief Executive Officer of Allergan, Inc. where, over 17 years in this role, he transformed the company from a small eye care business with $1 billion in annual sales into a global specialty pharmaceutical and medical device company with 2014 annual sales of over $7 billion and more than 10,000 employees. Before that, he served as Head of the Novartis Nutrition Division and served as a member of the Executive Committee of Novartis AG.

In addition to Pliant, David currently serves as a member of the Board of Directors of Alnylam Pharmaceuticals and BioMarin Pharmaceutical and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company. David will also be the Governing Body Chair of London Business School from 1 May 2023. 

David also serves as Deputy Chairman of the Governing Board of the London Business School, President of the Ophthalmology Foundation, President of the Advisory Board of the American Academy of Ophthalmology and is a member of the Executive Committee and Trustee of the California Institute of Technology.

David holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.

Dr. Andy Richards CBE

Founder of The Cambridge Angels and Chairman of the Babraham Campus

Dr. Andy Richards is an entrepreneur/investor with a track record in founding and scaling innovative healthcare companies. He is currently Chair of Arecor, ieso, Congenica, Closed Loop Medicine and Owlstone Medical; is a director of Our Future Health and RNAvate, a council member of the UKRI MRC, a founder member of Cambridge Angels and an advisor to several investment funds. 

Andy’s career started at AstraZeneca/ICI before returning to Cambridge at the beginning of UK Biotech where he founded Chiroscience, and since its merger with Celltech (1999) he has founded, invested in and scaled more than 30 innovative ventures. 

Invent Panel | Leading impactful healthcare innovation: The role of entrepreneurship
3rd April 5:30pm-6:30pm BST

James Roberts

Co-Founder and CEO
mOm Incubators

Karen Photo 2
Dr. Karen Skinner

Chief Project and Portfolio Officer

John Goldader

Managing Director and Partner
Boston Consulting Group London

melissa morris
Melissa Morris

CEO and Founder of Lantum

Prof. Nicos Savva

Professor of Management Science and Operations, London Business School (Moderator)

Laura Lane, PhD

Vice President - Europe Head of Lilly Ventures, Eli Lilly and Company

Laura Lane, PhD, is currently VP Lilly Ventures and the regional Head of Lilly Ventures for Eli Lilly & Company. Her focus is on Lilly’s venture capital strategy for Europe covering both direct investments into biotech and life science companies, and fund-of-fund relationships and investments, as well as supporting wider external innovation efforts across Lilly. 

Laura is a PhD-trained scientist with diverse scientific, business, transaction and operational experience. Her experience spans: venture capital; technology transfer; the charity sector; founding and leading biotech and life science start-ups; life science consulting as well as now pharma. Prior to Lilly, Laura was part of the investment team at Advent Life Sciences; selected investments included Highlight Therapeutics (Madrid, Spain), MiroBio (Oxford, UK) (acquired by Gilead Sciences August 2022), PIC Therapeutics (Boston, USA) and Proximie (London, UK). Prior to Advent, Laura held CEO and COO positions at several UK life science/biotech companies in Birmingham, Oxford & London. 

Laura gained her masters and doctorate from the University of Cambridge and currently serves on the boards of the non-profit Collaborative Community against Coronavirus (3CCorona) CIC and the UK’s BioIndustry Association (BIA). 

Appy Panel | Applying technology to healthcare practice: Opportunities & challenges
3rd April 7:30pm-8:30pm BST

Dr. Masood Ahmed

Board Trustee Great Ormond Street Hospital Children's Charity, NHS leader in digital transformation

Julia Strandberg Headshot given from adrienne (4)
Julia Strandberg

EVP and Chief Business Leader of Connected Care and Monitoring, Executive Committee member

Peter Ellingworth
Peter Ellingworth

Chief Executive
Association of British HealthTech Industries (ABHI)

ShanX-Medtech-Dr.-David-Hampton (1)
Dr. David Hampton

Programme Director for Bioscience Enterprise at the Biotechnology Institute
University of Cambridge

Day 2- 4th April 2024

Iskra Reic

Executive Vice-President (EVP), Vaccines & Immune Therapies at AstraZeneca

Iskra Reic serves as the Executive Vice-President (EVP), Vaccines & Immune Therapies at AstraZeneca, and is responsible for both the early and late-stage development of the Unit’s pipeline and portfolio, as well as medical affairs, marketing, and commercial operations.

Since joining AstraZeneca in 2001, she has held many roles including GM of Russia, Area VP for Russia and Eurasia, and the EVP of Europe & Canada.

Iskra trained as a Doctor of Dental Medicine at the Medical University of Zagreb, Croatia. She has an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia.   

Assess Panel | Democratising progress: The regulation of scientific innovation 6:00pm-7:00pm BST

Dr. James Duboff

Strategic Partnership Director
Genomics England

Eileen Tanghal (5)
Eileen Tanghal

Co-Founder at Black Opal Ventures
Former Senior Partner and MD at In-Q-Tel, Former VP at ARM

Dr. Virginia Acha

Associate Vice President – Global Lead, Global Regulatory Policy
Merck Sharp & Dohme (MSD)

Scale Panel | Empowering millions through inclusive consumer healthcare 7:30pm-8:30pm BST

Prof. Kamalini Ramdas

Professor of Management Science and Operations, London Business School

Anna Nightingale

VP Head of R&D EMEA-LatAm

Adel baluch
Dr. Adel Baluch

Director of Medical Affairs (Global)
Ada Health

Richard Meddings

Chairman of the Board, NHS England

Richard Meddings joined the Board of NHS England as Chair in March 2022. 

From 2002 to 2014, Richard was a Group Executive Director at Standard Chartered, and Group Finance Director for eight years. Prior to that he was Group Finance Director at the Woolwich and Group Financial Controller of Barclays. He has in the past been Chairman of TSB Bank, served on the Board of HM Treasury, as a Non-Executive Director on the Boards of Credit Suisse, Legal & General, 3i Group, Jardine Lloyd Thompson Group and at Deutsche Bank A.G. He has in these roles variously chaired Audit, Risk and Remuneration Committees. He has additionally sat as a panel member for HM Treasury on several Major Projects Reviews and undertaken Independent Commercial Assessments of DFID and of the FCO. 

From 2004 to 2014, Richard was Chairman of Seeing is Believing, a charity focused on curing avoidable blindness. He was a Trustee, and more recently Deputy Chair, of Teach First from 2016 to January 2022 and served on behalf of the Department of Education, for four years as Chairman of the Hastings Opportunity Area. 

He is an Associate of the Institute of Chartered Accountants in England and Wales, attended Wolverhampton Grammar School and has a Degree in Modern History from Exeter College, Oxford. Richard is married, with three adult children, and lives in East Sussex.